Start with the surprising number. A CRISPR patent search in the patent record returns tens of thousands of records, and the year-over-year distribution doesn't look like a maturing field — it looks like one still climbing. The annual counts move from the low hundreds in 2015 into the multiple thousands per year by the mid-2020s. By the numbers, gene editing is still in its expansion phase.

Here's what's behind it. A decade after CRISPR's breakout, you'd expect the patent curve to flatten as the foundational claims settle. Instead, the filings keep coming, because the platform keeps branching: new Cas enzymes, base editors, prime editors, delivery methods, and disease-specific applications each open fresh patentable territory. The recent grant record shows this directly — the Broad Institute's US12644111B2 ("CRISPR enzymes and systems," 2026) is a new enzyme-and-system grant, not a re-assertion of old claims.

“The present disclosure provides for systems, methods, and compositions for targeting nucleic acids.”— U.S. Patent No. 12,644,111 source

The activity also spreads across assignees, which is the tell that this is a field, not a monopoly. The recent CRISPR grant record includes the Broad Institute (US12644136B2, delivery to hematopoietic stem cells), Vertex on the application side (US12644137B2, hemoglobinopathies), and a long tail of universities and companies. Three filings pointing the same way isn't noise — it's a pattern of many players still staking claims.

A caution on reading these counts, because correlation isn't causation. A rising patent count doesn't prove rising innovation quality — it can reflect defensive filing, continuations, and thicket-building as much as genuine breakthroughs. The honest statement is narrow: filing velocity is high and not declining. What that velocity means for any one company's moat is a separate question the raw counts can't answer.

Still, the direction is informative for a generalist. When a technology's patent filings are still accelerating a decade after its debut, the commercial fight over who owns what is intensifying, not resolving. For investors and newcomers, that means licensing complexity — and litigation risk — is more likely to grow than shrink in the near term.

The bottom line, by the numbers: CRISPR is not a settled estate. The filing curve is still bending upward, the grants are spread across many assignees, and the platform keeps generating new patentable layers. Anyone treating gene-editing IP as "already decided" is reading a different chart than the one the patent record's counts actually show.